Canadian Cancer Trials Group Bulletins


Canadian Cancer Trials Group OV.19 (MRC ICON7) in the NEJM

Results of Canadian Cancer Trials Group OV.19 (MRC ICON7) -- A Randomized, Two-Arm, Multi-Centre Gynecologic Cancer Intergroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin And Paclitaxel) in Patients with Epithelial Ovarian Cancer -- were published in the 29 December 2011 issue of the New England Journal of Medicine.

The authors concluded that "for the whole ICON7 patient population, the overall magnitude of the benefit with respect to progression-free survival was relatively modest after the addition of bevacizumab to platinum-based chemotherapy and maintenance bevacizumab for the 12-cycle extension after chemotherapy was completed. Some will argue that final overall survival data are needed before the results can be fully interpreted. The apparently greater effect of bevacizumab in patients with a poor prognosis is encouraging."

Final results for overall survival rates should be available in 2013.

Please following this link for the complete publication ...